GLOW (BPC-157 + TB-500 + GHK-Cu)

How GLOW (BPC-157 + TB-500 + GHK-Cu) works in the body

Dosing evidence

4. The Current “Typical Dose 2.8 mg” Is

Community Dosing

The 2.8 mg number is mathematically coherent if the vial actually contains the 50/10/10 formulation.

At that ratio:

2.8 mg total blend contains approximately:

• 2 mg GHK-Cu

• 400 mcg BPC-157

• 400 mcg third peptide

That matches the current Navaro page and PeptideFox's standard community dose. (navarohealth.com) But that only proves:

the blend math works.

It does not prove:

2.8 mg is clinically optimal.

PeptideDosages uses a different community protocol:

2.33 mg daily which provides approximately:

• 1.7 mg GHK-Cu

• 330 mcg BPC-157

• 330 mcg TB-500

for four weeks. (peptidedosages.com) Verdict Change:

Typical dose: 2.8 mg to something like:

Common community dose example: 2.8 mg total blend, formulation-dependent And always display the component breakdown.

5. “Standard Protocol” Is Too Strong

Current Navaro:

2.8 mg daily, 5 days on / 2 days off for 12 weeks. (navarohealth.com) PeptideFox currently uses a different phased community framework:

• Weeks 1–4: daily

• Weeks 5–8: 5x/week

• Weeks 9–12: 2–3x/week. (peptidefox.com)

PeptideDosages uses:

• daily for 4 weeks

• then 2–4 weeks off. (peptidedosages.com)

That disagreement is informative.

There is no standardized GLOW protocol.

Correct heading Replace:

Standard Protocol with:

Community Protocol Examples Then compare them honestly.

6. The “5 Days On / 2 Days Off Prevents Copper

Toxicity” Claim Should Be Removed

The current page says the weekend break is:

“strictly” required to prevent copper toxicity. (navarohealth.com) I found no clinical evidence establishing that:

five days of GLOW followed by two days off prevents copper accumulation or toxicity.

There is no demonstrated copper threshold that suddenly resets over a weekend.

Verdict Unsupported biological rationale The schedule may be a community convention.

It should not be presented as a toxicity-prevention mechanism.

Better wording Some community protocols use 5 days on / 2 days off, but no human study has demonstrated that this schedule is necessary to prevent copper toxicity.

7. The Zinc-Depletion Section Is One of the

Biggest Errors on the Current Page

The page currently says injectable GHK-Cu:

• competes with zinc for intestinal absorption

• progressively depletes zinc

• makes zinc deficiency a contraindication

• requires 15–30 mg/day zinc supplementation. (navarohealth.com)

That mechanism is backwards and route-mismatched.

The established nutritional interaction is:

high zinc intake can interfere with copper absorption in the intestine.

NIH specifically warns that prolonged high-dose zinc can produce copper deficiency. (ods.od.nih.gov) That is not the same thing as:

injected copper causes zinc deficiency by outcompeting intestinal zinc absorption.

An SC injection also does not pass through the intestinal absorption step in the first place.

Major correction Remove:

• “zinc deficiency is a contraindication”

• “GHK-Cu progressively depletes zinc”

• “mandatory zinc supplementation”

• “15–30 mg zinc required throughout all cycles”

unless there is direct clinical evidence for the exact claim.

Important safety point Unnecessary zinc supplementation itself is not harmless. NIH notes that sustained high-dose zinc can impair copper absorption and reduce copper status. (ods.od.nih.gov) Verdict Current zinc logic should be removed.

8. Copper Exposure Still Matters, but It Needs to

Be Discussed Correctly

GHK-Cu does contain copper.

Therefore repeated systemic exposure can reasonably raise questions about:

• total copper exposure

• copper metabolism disorders

• hepatic handling

• exact dose

But the current page jumps too quickly from that fact to specific toxicity-prevention schedules and mandatory zinc therapy.

Better approach For the exact product, document:

• mg GHK-Cu per injection

• estimated copper content

• injection frequency

• duration

• other copper sources

Then state:

The clinical significance of chronic systemic copper exposure from injectable GHK-Cu has not been well established.

That is more accurate.

9. FDA's Injectable GHK-Cu Warning Needs to Be

Much More Prominent

FDA currently states:

compounded injectable GHK-Cu may pose immunogenicity risk because of potential aggregation and peptide-related impurities.

FDA also says human data are limited. (fda.gov) The 2026 503A update makes an important route distinction:

GHK-Cu except injectable routes is currently being evaluated separately, while injectable GHK-Cu carries the safety concerns above.

(fda.gov) Production wording FDA has specifically identified compounded injectable GHK-Cu as raising potential immunogenicity concerns involving aggregation and peptide-related impurities, with limited human safety data.

This belongs near the top safety summary.

Cycle

Current Navaro uses:

12 weeks. (navarohealth.com) PeptideFox uses:

12 weeks. (peptidefox.com) PeptideDosages uses:

4 weeks. (peptidedosages.com) That difference itself tells us:

the cycle is community convention, not biologically established.

Verdict Do not claim:

• 4 weeks is required

• 8 weeks is required

• 12 weeks is required

• weekend breaks are required

• washouts are required

18. Daily Use Is Community-Derived

Daily administration is common across community GLOW protocols.

But there is no exact-blend human dose-frequency trial establishing that daily administration is superior to:

• 5x/week

• 3x/week

• another schedule

Verdict Community precedent not:

clinically optimized frequency

19. Morning / Evening / Fasted / Exercise Timing

There is no controlled evidence showing GLOW should be administered:

• morning

• evening

• fasted

• fed

• before exercise

• after exercise

Current Navaro's:

Anytime is actually acceptable as long as it is understood to mean:

no timing advantage has been demonstrated. (navarohealth.com)

20. “Dopamine Buffer” Should Be Removed

The current profile includes:

Properties: Dopamine Buffer. (navarohealth.com) That is not a clinically recognized pharmacological classification for GLOW.

The page then attributes:

• lethargy

• sedation

• anhedonia

to dopaminergic effects of BPC-157/TB-500. (navarohealth.com)

BPC-157 has experimental literature involving several neurotransmitter systems, but that does not establish:

GLOW as a dopamine-buffering treatment or make sedation/anhedonia established blend adverse effects.

Verdict Remove:

Dopamine Buffer from the compound profile.

Protocol Logic Check

Question Verdict Is GLOW one standardized approved drug?

No Common 50/10/10 mg formulation documented in community sources?

Yes Is every GLOW vial necessarily 50/10/10?

No Exact third peptide must be confirmed?

Yes Is full-length Tβ4 the same as TB-500 LKKTETQ?

No Human full-length thymosin β4 research exists?

Yes FDA identified human exposure data for TB-500 fragment?

No Human trial of exact GLOW blend found?

No 2.8 mg blend dose mathematically coherent for 50/10/10?

Yes 2.8 mg clinically validated?

No Daily dosing clinically validated?

No 5 days on / 2 days off clinically validated?

No Does weekend skipping prevent copper toxicity?

Not established Is a 12-week cycle required?

No Does GLOW need receptor resetting?

No evidence Does injected GHK-Cu cause zinc deficiency through intestinal competition?

Unsupported / route-mismatched Is mandatory 15–30 mg zinc established?

No Does GHK-Cu have legitimate component evidence?

Yes Is human GHK-Cu evidence stronger topically?

Yes Does BPC-157 have strong human efficacy evidence?

No Does full-length Tβ4 have some human wound evidence?

Yes Does that validate injected GLOW for skin?

No Is “Dopamine Buffer” a validated GLOW property?

No Is active cancer an official absolute contraindication?

No Copper disorders warrant caution?

Yes Exact-blend same-vial stability established?

No Universal 28-day stability established?

No FDA approved?

No

Community Protocol Comparison

Current Navaro

2.8 mg total

providing:

• 2 mg GHK-Cu

• 400 mcg BPC-157

• 400 mcg third peptide

daily, with:

5 days on / 2 days off for:

12 weeks. (navarohealth.com) Classification Community protocol The component math is valid for a 5:1:1 blend.

The cycle logic is not clinically validated.

PeptideFox

PeptideFox describes a 70 mg blend containing:

• 50 mg GHK-Cu

• 10 mg BPC-157

• 10 mg full-length thymosin β4

with a standard:

2.8 mg total dose and a phased 12-week schedule:

Weeks 1–4: daily Weeks 5–8: 5x/week Weeks 9–12: 2–3x/week. (peptidefox.com) Important PeptideFox itself states:

no controlled GLOW trial establishes the results timeline and the complete blend has not been clinically tested. (peptidefox.com) Classification Community/practitioner protocol

PeptideDosages

PeptideDosages describes:

2.33 mg SC daily for:

4 weeks followed by:

2–4 weeks off.

It uses a 70 mg formulation and calculates roughly:

• 1.7 mg GHK-Cu

• 330 mcg BPC-157

• 330 mcg TB-500

per injection. (peptidedosages.com) It explicitly invokes:

receptor resetting for the break. (peptidedosages.com) Audit verdict The dose is useful as a community protocol example.

The receptor-reset claim should not be carried into Navaro.

Strongest Community Agreement

The sources agree fairly well on:

• approximately 50/10/10 formulation

• subcutaneous community use

• daily or near-daily early use

• GHK-Cu as the largest component

• skin/tissue-remodeling positioning

They do not agree on:

• exact daily dose

• frequency

• cycle length

• maintenance schedule

• washout

• third-peptide nomenclature

• storage period

That is exactly why Navaro should not call one schedule:

the standard clinical protocol.

Dose Classification

2.8 mg is a common community dose for a 50/10/10 mg GLOW formulation, not a clinically validated treatment dose.

Zinc Correction

The established nutritional interaction runs mainly in the opposite direction: high oral zinc can reduce intestinal copper absorption. There is no established evidence that SC GHK-Cu requires routine zinc supplementation because it “outcompetes zinc” in the intestine. (ods.od.nih.gov)

FDA Component Warning

All three components require regulatory caution. FDA has raised immunogenicity/characterization concerns for BPC-157 and injectable GHK-Cu, while FDA's TB-500 review found no identified human exposure data for the LKKTETQ fragment. (fda.gov)

Protocol logic check

No clinically established GLOW dose or cycle.

Medical literature and study context

GLOW Audit

I audited GLOW against the current live Navaro page and the same source hierarchy we have been using for the other compounds: FDA, PubMed, ClinicalTrials.gov/current human literature, plus PeptideFox and PeptideDosages for community-protocol comparison.

This page needs a major revision before production. The current page has a good skeptical disclaimer, but several of the actual protocol, safety, and mechanism statements underneath it are much more confident than the evidence supports. (navarohealth.com)

Current Page

GLOW (BPC-157 + TB-500 + GHK-Cu) Current live Navaro page:

https://navarohealth.com/library/glow-blend The page currently describes GLOW as an aesthetics/repair blend and lists:

Route: Subcutaneous Typical dose: 2.8 mg Timing: Anytime Targets: VEGFR2; G-Actin; MMP.

(navarohealth.com) It gives a “Standard Protocol” of:

2.8 mg daily for:

12 weeks with:

5 days on / 2 days off and says this schedule is used:

“to prevent copper toxicity.” (navarohealth.com) It also gives a lower-dose 1.4 mg daily protocol and makes several strong claims about zinc depletion, copper accumulation, dopamine effects, cancer risk, liver enzymes, and mandatory supplementation.

(navarohealth.com)

Overall Verdict

Major revision needed The biggest problems are:

• GLOW is not a standardized clinical product

• the exact product identity, particularly TB-500 versus full-length thymosin β4, must be clarified

• no human clinical trial validates the exact fixed-ratio GLOW blend

• “Standard Protocol” is too strong

• 2.8 mg daily is a community protocol, not a clinical dose

• the 5-days-on / 2-days-off rule has no demonstrated copper-toxicity rationale

• the claim that injected GHK-Cu progressively depletes zinc through intestinal absorption competition is

not supported and is mechanistically mismatched to SC administration

• mandatory 15–30 mg/day zinc supplementation is not justified

• “receptor resetting” is not supported

• several listed side effects are speculative community claims

• “active cancer = absolute contraindication” is too strong

• full-length thymosin β4 human evidence cannot be transferred automatically to TB-500 fragment

LKKTETQ

• generic 4-week post-reconstitution stability is not validated for every GLOW formulation

• same-vial compatibility of the three ingredients has not been clinically established

• FDA currently has significant safety concerns involving all three injectable components in the way these

community blends are marketed. (fda.gov)

1. First Problem: What Exactly Is in “GLOW”?

The current page calls the blend:

BPC-157 + TB-500 + GHK-Cu. (navarohealth.com) A common 2026 community formulation is:

GHK-Cu: 50 mg BPC-157: 10 mg Thymosin β4 / “TB” component: 10 mg for:

70 mg total or a:

5 : 1 : 1 mass ratio.

PeptideFox currently describes its GLOW formulation specifically as 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg full-length thymosin β4, and explicitly says it means the full 43-amino-acid thymosin β4 molecule rather than the shorter TB-500 fragment. (peptidefox.com) PeptideDosages, however, describes a 70 mg formulation as:

GHK-Cu + BPC-157 + TB-500. (peptidedosages.com) This distinction matters enormously.

“GLOW” is therefore a:

community/vendor formulation name not one scientifically standardized fixed-dose drug.

Production requirement Near the top of the page, identify the exact formulation:

GHK-Cu: ___ mg BPC-157: ___ mg Third peptide: ___ mg Exact identity of third peptide: full-length thymosin β4 OR TB-500 fragment Do not leave that last part ambiguous.

2. TB-500 and Full-Length Thymosin β4 Are Not

Automatically the Same Thing

This is probably the most important scientific source-matching issue on the page.

FDA currently defines:

TB-500 in its compounding review as:

thymosin β4 fragment LKKTETQ.

FDA states that it has not identified human exposure data for drug products containing this thymosin β4 fragment. (fda.gov) Full-length thymosin β4 is a different molecule.

There is human clinical research involving full-length thymosin β4, including wound-healing research.

Phase 2 studies have investigated the full-length peptide in patients with difficult-to-heal wounds.

(pubmed.ncbi.nlm.nih.gov) Therefore:

If the GLOW vial contains:

full-length thymosin β4 then full-length Tβ4 literature may be relevant as component evidence.

If the vial contains:

TB-500 / LKKTETQ then those full-length human trials cannot simply be assigned to it.

Production wording “TB-500” is often used loosely online, but FDA uses the name for the shorter thymosin β4 fragment LKKTETQ. Full-length thymosin β4 has separate research and should not automatically be treated as the same administered compound. Confirm the actual sequence in the GLOW formulation.

This needs to be prominent.

3. No Human Clinical Trial Validates the Exact

GLOW Blend

The existing page actually acknowledges this in its evidence section, which is good. It says component evidence does not prove combined safety, compatibility, concentration, or route. (navarohealth.com) That principle needs to control the rest of the page.

The exact:

GHK-Cu + BPC-157 + thymosin β4/TB-500 fixed-ratio injectable formulation does not have a matching approved label or established human efficacy program.

Even PeptideFox's current GLOW comparison page explicitly states that no controlled study has tested GLOW as a combined fixed-ratio intervention. (peptidefox.com)

Evidence rating Exact GLOW blend human efficacy: Not established Dose-finding: Not established Long-term safety: Not established Human PK: Not established Optimal frequency: Not established Same-vial compatibility: Not established Validated cosmetic efficacy: Not established

10. BPC-157 Evidence Is Mostly Preclinical

BPC-157 has a substantial animal and mechanistic literature.

Recent reviews describe effects involving:

• angiogenesis

• fibroblast activity

• nitric oxide signaling

• tendon and muscle repair

• inflammatory pathways. (pubmed.ncbi.nlm.nih.gov)

But human evidence remains extremely small.

A 2025 pilot IV study administered BPC-157 to only:

two healthy adults at doses up to:

20 mg IV and reported no adverse effects in those two participants. (pubmed.ncbi.nlm.nih.gov) That is interesting early human exposure.

It is nowhere near enough to establish:

• daily 400 mcg SC efficacy

• cosmetic skin benefits

• chronic safety

• inclusion in GLOW

FDA continues to say it has only limited safety-related information for proposed BPC-157 routes and highlights possible immunogenicity and characterization concerns. (fda.gov) Evidence classification Preclinical: substantial Human: extremely limited Injected skin/aesthetic efficacy: unproven GLOW combination efficacy: unproven

11. The BPC-157 “Capillary Supply” Story Is

Mechanistically Plausible but Overstated

PeptideFox says BPC-157:

“sprouts new small blood vessels into the dermal repair area.” (peptidefox.com) Preclinical evidence does support angiogenic signaling involving VEGFR2 and nitric-oxide pathways.

(pubmed.ncbi.nlm.nih.gov) But there is no human GLOW trial demonstrating that injected BPC-157:

• increases dermal capillary supply

• improves skin collagen because of that effect

• improves GHK-Cu efficacy

Better wording BPC-157 has angiogenesis and vascular-repair effects in preclinical models, which provides a theoretical reason for including it in the blend. Whether that improves human skin outcomes in GLOW has not been demonstrated.

12. GHK-Cu Evidence Is Real, but Mostly Not

Injectable GLOW Evidence

GHK-Cu has substantial research involving:

• tissue remodeling

• wound biology

• collagen

• extracellular matrix

• antioxidant signaling. (pubmed.ncbi.nlm.nih.gov)

But human evidence is much stronger for:

topical exposure than community SC injection protocols.

Even a human topical study following laser resurfacing did not show every proposed benefit, which is a useful reminder not to oversell the component. (pubmed.ncbi.nlm.nih.gov) Verdict GHK-Cu component evidence belongs on the page.

But the page must repeatedly distinguish:

GHK-Cu biology from:

injected GLOW efficacy.

13. Full-Length Thymosin β4 Has Human

Research

Unlike TB-500 fragment LKKTETQ, full-length thymosin β4 does have human wound research.

Clinical work has included difficult-to-heal:

• pressure ulcers

• stasis ulcers

• other wound settings

and has reported accelerated healing in some studies. (pubmed.ncbi.nlm.nih.gov) But:

That does not validate:

• 400 mcg SC daily

• cosmetic skin use

• the GLOW ratio

• 12-week GLOW cycles

Evidence verdict Full-length Tβ4 has human component evidence.

GLOW does not inherit a clinical protocol from those trials.

14. FDA's TB-500 Review Is a Major 2026 Update

FDA's 2026 review of TB-500-related bulk substances is highly relevant.

FDA defines the substance under review as the:

LKKTETQ thymosin β4 fragment and concluded that available information was insufficient to establish human safety and effectiveness.

FDA proposed that:

• TB-500 free base

• TB-500 acetate

not be included on the 503A Bulks List. (fda.gov) The July 23, 2026 PCAC meeting considered both BPC-157 and TB-500. Advisory committee recommendations are nonbinding, and FDA rulemaking/status should not be described as final approval simply because a committee considered or voted on a substance. (fda.gov) Production rule Do not say:

“FDA approved compounded TB-500.”

Do not say:

“TB-500 is FDA approved because PCAC recommended it.”

It is not.

15. The Exact Thymosin Species Must Match the

Evidence

This deserves its own Protocol Logic Check row.

If Navaro's blend actually contains:

TB-500 fragment LKKTETQ then:

full-length Tβ4 human wound studies ≠ TB-500 human evidence.

If it contains:

full-length thymosin β4 then FDA's “no identified human exposure” statement for the LKKTETQ fragment should not be falsely applied as though it describes full-length Tβ4.

Verdict Exact sequence/form must be confirmed before assigning evidence.

16. “Receptor Resetting” Should Be Removed

PeptideDosages says its 4-week schedule is followed by 2–4 weeks off to:

“allow receptor resetting.” (peptidedosages.com) There is no established single:

GLOW receptor to reset.

The blend contains mechanistically different compounds:

• GHK-Cu

• BPC-157

• thymosin β4/TB-500

None creates a demonstrated clinical need for a scheduled 2–4 week receptor reset.

Verdict Unsupported

17. There Is No Evidence-Based 8- or 12-Week

32. FDA 2026 Regulatory Picture

This needs a much stronger section.

BPC-157

FDA says compounded BPC-157 may raise:

• immunogenicity

• peptide impurity

• API-characterization

concerns and says it has limited safety information for proposed routes. (fda.gov) In July 2026, FDA evaluated BPC-157 free base and acetate for possible inclusion on the 503A Bulks List and proposed against inclusion in its briefing materials. (fda.gov)

TB-500

FDA's current review defines TB-500 as:

thymosin β4 fragment LKKTETQ and states it has not identified human exposure data for drug products containing that fragment. (fda.gov) FDA's July 2026 evaluation concluded that information on:

• chemical characterization

• clinical safety

• effectiveness

was insufficient and proposed that TB-500 free base and acetate not be placed on the 503A Bulks List.

(fda.gov)

GHK-Cu

For injectable GHK-Cu, FDA highlights:

• possible immunogenicity

• aggregation

• peptide-related impurities

• limited human safety information. (fda.gov)

Noninjectable GHK-Cu is currently being evaluated separately under FDA's 503A framework. (fda.gov)

Exact GLOW Blend

FDA approved?

No Approved fixed-ratio GLOW product?

No FDA-approved dosing?

No FDA-approved cosmetic indication?

No

Recommended Evidence Ladder

Exact GLOW blend: Very limited Human clinical dose for GLOW: Not established Human efficacy for injected GLOW: Not established GHK-Cu biology: Moderate/strong mechanistic and preclinical evidence Human topical GHK-Cu: Limited but real Injectable GHK-Cu: Limited, with FDA safety concerns BPC-157 preclinical: Substantial BPC-157 human research: Extremely limited Full-length thymosin β4 human evidence: Limited but real, including wound research TB-500 LKKTETQ human exposure evidence: FDA says none identified Community GLOW protocols: Common Same-vial compatibility: Not established FDA-approved GLOW: No

What the Current Page Gets Right

I would keep these concepts:

• exact blend is not independently clinically validated

• evidence strength should remain very limited

• component studies do not prove the combination

• subcutaneous use is community/research context

• no FDA-approved regimen exists

• long-term data are limited

• blend compatibility requires caution. (navarohealth.com)

The page's foundational skepticism is good.

The problem is that the later protocol and safety sections then become much more definitive than that evidence rating allows.

What I Would Remove

Remove:

“strictly 5 days on / 2 days off to prevent copper toxicity.”

Remove:

“daily GHK-Cu progressively depletes zinc.”

Remove:

“zinc supplementation 15–30 mg/day is required.”

Remove:

“zinc deficiency is a contraindication.”

Remove:

“active cancer is absolutely contraindicated because BPC-157 would accelerate tumor growth.”

Replace with a cautious mechanistic discussion.

Remove:

“Dopamine Buffer.”

Remove established-sounding claims that:

• GLOW causes anhedonia

• GLOW predictably causes sedation

• GLOW commonly raises ALT/AST

• weekend breaks prevent copper toxicity

• cycle limits prevent copper accumulation

• the blend was specifically engineered to reduce GHK-Cu injection pain

unless exact supporting evidence is available.

Remove:

receptor reset from any protocol.

What Needs to Be Added

Exact Formula / Identity Box

GLOW is not a standardized drug name. Confirm the amount and exact identity of all three components.

In particular, determine whether the third ingredient is full-length thymosin β4 or the shorter LKKTETQ fragment commonly called TB-500.

TB-500 vs Thymosin β4 Warning

Full-length thymosin β4 and TB-500 fragment LKKTETQ are not interchangeable evidence sources.

Human studies of full-length thymosin β4 should not be cited as proof of efficacy or safety for the TB-500 fragment.

Final Audit Verdict

The current GLOW page is not publish-ready as written.

Its strongest feature is the correct high-level statement that the exact blend has very limited evidence.

(navarohealth.com) Its biggest weakness is that it then presents a community protocol and several theoretical safety ideas almost as established pharmacology.

The production page should be built around these rules:

1. GLOW is a community/vendor blend, not an FDA-approved standardized drug.

2. Confirm whether the third component is full-length thymosin β4 or TB-500 fragment LKKTETQ. Those are not interchangeable evidence sources.

3. 2.8 mg is a common community dose for the 50/10/10 formulation, not a clinically validated GLOW dose.

4. Replace “Standard Protocol” with “Community Protocol Examples.”

5. Remove the claim that 5 days on / 2 days off is required to prevent copper toxicity.

6. Remove the current zinc-depletion mechanism and mandatory zinc supplementation. The established oral interaction is high zinc impairing copper absorption, not injected GHK-Cu necessarily causing zinc deficiency through intestinal competition. (ods.od.nih.gov) 7. Remove receptor-reset logic.

8. Do not call active malignancy an established absolute GLOW contraindication. Keep angiogenesis/growth-signaling concerns as theoretical clinical cautions.

9. Remove “Dopamine Buffer” and downgrade sedation, anhedonia, headache, elevated LFTs and similar claims unless directly supported.

10. Put FDA's component-specific concerns prominently near the top: BPC-157 has limited human safety information, injectable GHK-Cu has aggregation/immunogenicity concerns, and FDA says it has not identified human exposure data for TB-500 fragment LKKTETQ. (fda.gov) 11. Keep human full-length thymosin β4 wound studies clearly separated from TB-500-fragment evidence.

12. Do not use a universal four-week or 28-day post-reconstitution stability rule for every GLOW vial.

Once those changes are applied, GLOW can be made publish-ready in the same format as GGH, Retatrutide, and the other finalized compounds.

Independent evidence

Very limited for the exact blend

A mathematically consistent blend ratio does not validate efficacy, same-vial stability, cycling, or long-term safety.

Storage

30. Generic Four-Week Stability Should Not Be

Used as Clinical Fact

PeptideDosages says reconstituted GLOW should be refrigerated and used within:

4 weeks. (peptidedosages.com) That is community product-handling guidance.

It is not universal clinical stability evidence for every GLOW formulation.

Correct wording Some community sources use a four-week refrigerated window, but no universal validated post-reconstitution stability period exists for all GLOW formulations. Follow exact formulation-specific stability information.

31. “Pre-Mixed: No” Is Inconsistent With the Way

GLOW Is Actually Defined

Current Navaro says:

Pre-mixed: No. (navarohealth.com) But GLOW is generally discussed in current community sources specifically as a:

single-vial fixed-ratio blend.

PeptideFox explicitly calls it a pre-mixed 70 mg blend. (peptidefox.com) Verdict If Navaro means the GLOW entry itself:

Pre-mixed should probably be Yes / formulation-dependent.

If the site means users could assemble the components separately, that should be explained instead.

Contraindications & cautions

Contraindication”

The existing page gives an extremely confident explanation that BPC-157 angiogenesis and GHK-Cu growth signaling would accelerate tumor growth and calls active malignancy an:

absolute contraindication. (navarohealth.com) That is too strong.

Mechanistic concerns around:

• angiogenesis

• tissue remodeling

• growth signaling

can reasonably justify caution.

But there is no approved GLOW label or clinical oncology dataset establishing:

active malignancy as a formal absolute contraindication.

Correct classification Theoretical / clinically important caution not:

formal contraindication

24. Wilson Disease / Copper-Metabolism

Disorders

This one deserves more respect than the cancer statement because the blend contains a copper complex.

Wilson disease causes abnormal copper accumulation.

Adding a systemic copper-containing experimental product would raise obvious clinical concerns.

But:

There is still no FDA-approved GLOW label.

Classification Strong biological caution rather than pretending it is an official GLOW-label contraindication.

25. Pregnancy / Breastfeeding

No good exact-blend pregnancy safety data exist.

Classification Safety unknown / avoid extrapolation not a formal FDA GLOW contraindication because no such label exists.

26. “Severe IBD Flare” Claims Need Removal

The current page gives detailed instructions about GLOW being acceptable for:

remission maintenance but inappropriate for acute severe IBD. (navarohealth.com) There is no controlled human GLOW program establishing:

• treatment of IBD remission

• flare management

• GLOW maintenance therapy

Verdict Remove this disease-management language.

It exceeds the evidence by a large margin.

Possible side effects

21. Several Current Side Effects Are Overstated

The current page lists things such as:

• sedation

• lethargy

• progressive zinc depletion

• copper accumulation

• headache

• elevated ALT/AST

• temporary inflammation

• anhedonia. (navarohealth.com)

For the exact GLOW blend, there is no controlled safety dataset establishing that profile.

Better classifications Injection-site pain / irritation: Plausible and community reported Nausea: Possible but not established as a characteristic exact-blend effect Headache: Nonspecific/community reported Fatigue: Community/uncertain Anhedonia: Community/uncertain, not established GLOW toxicity Elevated liver enzymes: Not established as a normal expected GLOW adverse effect Zinc depletion: Remove as currently framed Copper toxicity: Theoretical exposure concern requiring actual dose/formulation context

22. “The Blend Was Designed to Reduce GHK-Cu

Injection Pain” Is Not Established

The current page says the blend's:

“primary design purpose”

is to reduce GHK-Cu injection pain. (navarohealth.com) I found no clinical formulation study demonstrating that adding BPC-157 and thymosin β4:

• lowers GHK-Cu injection pain

• changes pH enough to improve tolerance

• produces a safer formulation

Verdict Remove unless a formulation-specific source exists.

23. Active Cancer Should Not Be an “Absolute

Compatibility

27. Combination “Synergy” Is Unproven

The current page lists:

• Ipamorelin

• AOD-9604

• Matrixyl

• SNAP-8

• KPV

as “Reported synergistic.” (navarohealth.com) No controlled evidence establishes those GLOW combinations as synergistic.

Replace with Commonly Paired With

Then classify each combination.

For example:

KPV: adds a different anti-inflammatory mechanism in community KLOW formulations, but no human GLOW-vs-KLOW trial exists. (peptidefox.com) Matrixyl / SNAP-8: topical cosmetic peptides; different route/context; no clinical injectable-GLOW synergy established.

Ipamorelin: unrelated GH-secretagogue pathway; no validated GLOW combination.

AOD-9604: unrelated metabolic/fat-loss research context; no demonstrated synergy.

28. Duplicate-Ingredient Stacking Should Be

Flagged

Adding separate:

• BPC-157

• TB-500/Tβ4

• GHK-Cu

• KLOW

on top of GLOW could duplicate ingredients.

The current page correctly flags some of these as incompatible, but “contraindicated” is probably too strong.

Better label Ingredient overlap / redundancy Because the problem is primarily:

you are doubling components whose actual combined exposure may be unclear.

29. Same-Vial Compatibility Is Not Established

Even if all three compounds have separate stability data, that does not prove:

the three-peptide mixture remains chemically and physically stable together.

Blend stability depends on factors such as:

• pH

• excipients

• concentration

• oxidation

• temperature

• storage time

• peptide adsorption

• aggregation

There is no FDA-approved reference GLOW formulation.

Verdict Formulation-specific compatibility data required

Sources

Sources I Would Use for the Production Page

1. Current Navaro GLOW Page For auditing the existing claims. (navarohealth.com) 2. FDA Significant Safety Risks Page Primary regulatory source for:

• BPC-157

• injectable GHK-Cu

• TB-500 LKKTETQ

safety/evidence limitations. (fda.gov) 3. FDA July 2026 BPC-157 / TB-500 PCAC Materials For current 503A regulatory evaluation.

FDA proposed against including BPC-157 and TB-500-related substances in its briefing materials; the advisory process itself should not be confused with drug approval. (fda.gov) 4. FDA May 2026 503A Update For the important injectable versus noninjectable GHK-Cu distinction. (fda.gov) 5. BPC-157 2025 Human IV Pilot For the very small amount of direct human exposure data.

Only two participants were included. (pubmed.ncbi.nlm.nih.gov) 6. Current BPC-157 Reviews For the strong preclinical / weak human-evidence distinction. (pubmed.ncbi.nlm.nih.gov) 7. Full-Length Thymosin β4 Human Wound Research For legitimate component-level human evidence, while keeping it separate from TB-500 fragment evidence. (pubmed.ncbi.nlm.nih.gov) 8. GHK-Cu Reviews For tissue-remodeling, collagen, and wound biology. (pubmed.ncbi.nlm.nih.gov) 9. NIH Copper / Zinc Fact Sheets For correcting the current zinc/copper mechanism. (ods.od.nih.gov) 10. PeptideFox GLOW Evidence type: Community/practitioner protocol Useful for:

• 50/10/10 formulation

• 2.8 mg community dose

• phased 12-week protocol

• full-length Tβ4 interpretation

• explicit acknowledgment that the blend itself lacks a controlled trial. (peptidefox.com)

11. PeptideDosages GLOW Evidence type: Community protocol Useful for:

• 2.33 mg daily

• four-week protocol

• 70 mg product ratio

• showing disagreement in community schedules

but its “receptor reset” rationale should not be adopted. (peptidedosages.com)

Navaro Compounds.pdf, pages 331–356.